相关产品推荐更多 >

TNF-α Recombinant monoclonal antibody (CDP 571) (Human IgG4κ)
¥7683.98
Epithelial sodium channel (γ-subunit) monoclonal antibody (5c2) (biotin conjugate)
询价
IL-4 Recombinant monoclonal antibody (11B11) (Rat IgG1κ)
¥7683.98
His(6) Recombinant monoclonal antibody (Human IgG3κ)
¥7822.68
Complement factor H (human) monoclonal antibody (L20/3) (biotin conjugate)
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 抗体名:
InVivoPlus anti-mouse PD-1 (CD279)
- 抗体英文名:
InVivoPlus anti-mouse PD-1 (CD279)
- 靶点:
请见产品说明
- 浓度:
请见产品说明
- 应用范围:
in vivo blocking of PD-1/PD-L signaling
- 宿主:
Rat
- 适应物种:
Mouse
- 保质期:
请参考说明
- 抗原来源:
/
- 目录编号:
/
- 级别:
体内研究抗体
- 库存:
大量
- 供应商:
欣博盛生物科技有限公司
- 标记物:
无
- 克隆性:
单克隆
- 保存条件:
4度避光
- 形态:
液体
- 亚型:
Rat IgG2a
- 免疫原:
mouse PD-1 (CD279)
- 规格:
100 mg
InVivoPlus anti-mouse PD-1 (CD279) 产品介绍:
The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. Like the J43 antibody the RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1.
推荐的同型对照:
InVivoPlus rat IgG2a isotype control, anti-trinitrophenol(BP0089)
免疫原:Syrian Hamster BKH cells transfected with mouse PD-1 cDNA
内毒素水平:
<1EU/mg (<0.001EU/μg)
Determined by LAL gel clotting assay
纯度:
>95%
Determined by SDS-PAGE
组成:
PBS, pH 7.0
Contains no stabilizers or preservatives
蛋白分子量大小:150 kDa
保存条件:
The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
参考文献:
1.Grasselly, C., et al. (2018). "The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent." Front Immunol 9: 2100.
2.Triplett, T. A., et al. (2018). "Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme." Nat Biotechnol 36(8): 758-764.
3.Moynihan, K. D., et al. (2016). "Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses." Nat Med. doi: 10.1038/nm.4200.
4.Evans, E. E., et al. (2015). "Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies." Cancer Immunol Res 3(6): 689-701
关于BioXcell
BioXcell公司位于美国新罕布什尔州,具有超过15年单克隆抗体和重组蛋白生产及定制经验,可以为科研提供多种高品质的、临床前级别的单克隆抗体和重组蛋白。BioXcell通过大规模生产和亲和纯化抗体,可以提供50或100mg的大包装以及高达50g规格的抗体,所有抗体均具有高纯度、低内毒素、无防腐剂的特点,具有非常高的性价比。是您做小鼠体内研究不二的选择。BioXcell的热销抗体PD-1,PD-L1,CD4等,以及重组蛋白CTLA-4, Fit-3L等, 同型对照抗体mouse IgG,rat IgG均是您做体内研究的好帮手。
详情请咨询BioXcell全国授权一级代理-欣博盛生物科技
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验1.Grasselly, C., et al. (2018). "The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent." Front Immunol 9: 2100.
2.Triplett, T. A., et al. (2018). "Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme." Nat Biotechnol 36(8): 758-764.
3.Moynihan, K. D., et al. (2016). "Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses." Nat Med. doi: 10.1038/nm.4200.
4.Evans, E. E., et al. (2015). "Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies." Cancer Immunol Res 3(6): 689-701
技术资料暂无技术资料 索取技术资料




